AI medical device developer Imidex and DNA sequencing technology company Orbit Genomics have established a partnership to develop a combined approach for diagnosing lung cancer.
The companies are preparing to start clinical trials. Imidex's AI software VisiRad XR will be used to analyze chest x-rays and highlight possible lung nodules and masses. Orbit Genomics will then test those identified lung nodule patients with OrbiSeq-L, AI sequencing technology that provides highly specific insights about cancer from blood samples, Imidex said.
VisiRad XR was cleared by the U.S. Food and Drug Administration (FDA) in August 2023 and has demonstrated an 83% sensitivity in detecting lung nodules as small as 6mm, Imidex noted.
